Pay to Marwadi

Company Profile

BHARAT PARENTERALS LTD.

NSE : NABSE : 541096ISIN CODE : INE365Y01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE1681.00-15.8 (-0.93 % )
PREV CLOSE (Rs.) 1696.80
OPEN PRICE (Rs.) 1697.05
BID PRICE (QTY) 1657.85 (2 )
OFFER PRICE (QTY) 1680.95 (1 )
VOLUME 1929
TODAY'S LOW / HIGH (Rs.)1681.00 1738.95
52 WK LOW / HIGH (Rs.) 321.2 1824.7
NSE
This Company is not listed in NSE

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.04
TTM EPS (Rs.) 49.50
P/E Ratio 34.04
Book Value (Rs.) 362.89
Face Value (Rs.) 10
MCap (Rs. in Mn) 9806.14
Price/Earning (TTM) 27.99
Price/Sales (TTM) 4.09
Price/Book (MRQ) 4.64
PAT Margin (%) 9.63
ROCE (%) 16.62
Incorporation Year : 1992

Management Info :

- Chairman Bharat Desai - Managing Director

Registered Office :

Address : Survey No. 144 A,Jarod - Samlaya Road,Haripura, Savli,
Vadodara,
Gujarat-391520

Phone : 02667 - 251670, 251680, 9909928332

Website : www.bplindia.in

Registrar's Details : Adroit Corporate Services Pvt Ltd
18-20, 1st floor, Plot No 639,Makwana Road,,Marol, Andheri (East),Mumbai
Listing : BSE
NEWS More
29Apr04-29-2024$Allotment of Equity Shares Allotment of Equity Shares
Preferential Issue of shares Inter-alia, considered and approved the following: 1. To increase in Authorised Share Capital of the Company up to Rs.8,00,00,000/- The Board has approved the proposal of increase in Authorised Share Capital of the Company from Rs. 6,30,00,000/- (Rupees Six Crores Thirty Lakhs only) divided into 63,00,000 equity shares of Rs. 10/- (Rupees Ten) each to Rs. 8,00,00,000 (Rupees Eight Crores only) divided into 80,00,000 equity shares of Rs.10/- (Rupees Ten only) each by creation of additional Equity Shares amounting to Rs. 1,70,00,000/- (Rupees One Crore Seventy lacs Only) divided into 17,00,000 Equity Shares of Rs. 10/- (Rupees Ten Only) each raking pari-passu in all respect with the existing Equity Shares of the Company as per the Memorandum and Article of Association of the Company. 2. Raising of further capital by way of Issue, Offer and Allot of Equity Shares on a Preferential Basis The Board has approved raising of further capital of the Company by way of Issue, Offer and Allot up to approximately 7,23,607 (Seven Lakhs Twenty-Three Thousand Six hundred and Seven) fully paidup Equity Shares of with a face value of Rs. 10 (Rupees Ten only) ach ("Equity Shares") at a price of Rs. 1,356.40 (Rupees One Thousand and Three Hundred and Fifty-six point forty paise) (including a premium of Rs. 1,346.40 (Rupees One Thousand and Three Hundred and Forty-six point forty paise) per Equity Share aggregating to Rs. 98,15,00,000/- (Rupees Ninety-Eight Crores and Fifteen Lakhs Only) on Preferential basis subject to approval of the shareholders of the Company in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws.
Preferential Issue of shares Inter-alia, considered and approv..
22Mar03-22-2024$Bharat Parenterals informs about details of loss of certificate Bharat Parenterals informs a
Pursuant to Regulation 39(3) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 20 I 5, Bharat Parenterals has informed that the shareholder(s) has/have reported to the Company about loss of their share certificates. Name of the shareholder: Bharat Shah (Deceased); Folio No. BR01174.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39(3) of the SEBI Listing Obligations an..
13Mar03-13-2024$Bharat Parenterals’ arm signs deal with two Global Complex Generic marketing companies Bharat Parenterals’ arm si

Bharat Parenterals’ subsidiary Innoxel Lifesciences has signed a deal to out license seven complex molecules including two, 505(b) 2 products with two Global Complex Generic marketing companies. According to agreement, Innoxel Lifesciences will receive cumulative milestone payments of Rs 31 crore over the period of next three years (Rs 10.3 crore every year). Primary countries for Marketing will be United States and some of the European countries.

Innoxel Lifesciences has developed total twenty-two complex generic molecules, including seven 505(b) 2. Additional sixteen molecules are in pipeline and likely to be developed over the next two years. Innoxel Lifesciences has a state-of-the-art manufacturing facility with SKID based technology in Vadodara to manufacture these drugs. On successful filing and approval of these molecules, company will manufacture drugs on contract manufacturing basis and will also receive Profit Share income after commercialisation in the future.

Innoxel Lifesciences was incorporated in the year 2021 with the vision of developing and manufacturing of highly complex generic molecules, including 505(b) 2 for the regulated markets, mainly the United States and select Western European countries.

Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.

Bharat Parenterals’ subsidiary Innoxel Lifesciences has signe..
02Mar03-02-2024$Bharat Parenterals informs about analyst meet Bharat Parenterals informs a
Pursuant to Regulation 30 of the Listing Regulations read with clause 15(a) of Part A of Schedule III of the Listing Regulations, Bharat Parenterals has informed that two meeting is scheduled with the Analyst/ Institutional Investor for purpose of Investment in the Company on 6th March, 2024, in Mumbai. Further, the Investors' Presentations submitted vide its letter dated 20th February, 2024 and uploaded on website of the Company, will be made during the aforesaid meeting. The aforesaid information is also being placed on the website of the Company.
The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Listing Regulations read with..
03Feb02-03-2024$Bharat Parenterals informs about loss of share certificates Bharat Parenterals informs a
Pursuant to Regulation 39(3) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, Bharat Parenterals has informed that the shareholder(s) has/have reported to the Company about loss of their share certificates. The particulars of loss of share certificates are enclosed. In this regard, Adroit Corporate Services, RTA of company has verified the details and had informed the shareholder the necessary procedure for issue of duplicate share certificates. After receipt of valid documents, the Share certificates will be issued within the statutory time limit.

The above information is a part of company’s filings submitted to BSE. 

Pursuant to Regulation 39(3) of the SEBI Listing Obligations an..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit50.7243.4
Gross Profit 69 321.7
Operating Profit 91.8402.1
Net Sales 5882179.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Ajanta Pharma (BSE)
 2385.05 (6.80%)
M.Cap ( in Cr)
30085.03
Torrent Pharma (BSE)
 2760.15 (3.23%)
M.Cap ( in Cr)
93581.86
Astrazeneca Pharma I (BSE)
 5400.00 (1.24%)
M.Cap ( in Cr)
13451.75
Jenburkt Pharma (BSE)
 843.95 (5.33%)
M.Cap ( in Cr)
357.48
Dr. Reddy's Lab (BSE)
 6325.25 (0.59%)
M.Cap ( in Cr)
105896.24
Shareholding Pattern More
PROMOTERS 73.27 %
NON-INSTITUTION 26.73 %
FI/BANKS/INSURANCE 0.01 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS
Scheme NameHold(%)
No Data Found
F & O Quotes